Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company' or 'Jyong Biotech'), a science-driven biotechnology company dedicated to the ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ...

Are frequent nighttime pee runs making it difficult for you to get enough sleep? There's a less popular seed extract that may ...

Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis ...

You've probably had to wake up to pee at night but not poop, and that's thanks to surprisingly intelligent parts of your body ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

The structure of your business influences everything from taxes to day-to-day operations. Browse Investopedia’s expert written library to learn about sole proprietorships, LLCs, S-Corp, C-Corp, and ...